IR@PKUHSC  > 北京大学第一临床医学院  > 核医学科
18F-FDG PET/CT在Castleman病中的临床应用价值
其他题名Clinical value of 18F-FDG PET/CT in the management of Castleman's disease
付占立; 张旭初; 范岩; 张建华; 王荣福
关键词巨淋巴结增生 体层摄影术 脱氧葡萄糖 发射型计算机 体层摄影术 Giant Lymph Node Hyperplasia X线计算机 Tomography Deoxyglucose Emission-computed Tomography X-ray Computed
收录类别中国科技核心期刊 ; CSCD
文章类型Journal Article
摘要目的 评价18F-FDG PET/CT在Castleman病(CD)的临床分型、疗效评价及转化监测中的应用价值.方法 回顾性分析14例CD患者[年龄(45.64±14.30)岁,男、女各7例]的18F-FDGPET/CT影像表现(病灶数量、分布、SUVmax),比较不同临床分型、病理类型、病理转化患者的影像表现,并对4例化疗后复查18 F-FDG PET/CT患者的病灶影像学变化进行记录.数据比较采用Mann-Whitney及Kruskal-Wallis秩和检验.结果 12例病理未发生转化的CD患者,化疗前18 F-FDG PET/CT检查均有1个或多个淋巴结肿大且伴有葡萄糖代谢增高,SUVmax3.94± 1.44(1.9 ~ 6.8);临床类型为单中心(2/12)与多中心(10/12) CD的SUV max分别为4.55±3.18和3.82±1.14,差异无统计学意义(Z=0.22,P>0.05);病理类型分别为透明血管型(4/12)、浆细胞型(6/12)、混合型(2/12) CD的SUVmax分别为3.56±0.96、4.73± 1.41和2.30±0.57,差异无统计学意义(x2=4.74,P>0.05).4例(4/12)化疗后复查PET/CT的患者中,3例病灶完全消失,1例病灶缩小、代谢减低.2例(2/14)发生病理转化的患者,SUVmax10.85±2.05,高于未转化者(3.94±1.44;Z=-2.19,P<0.05).结论 18F-FDGPET/CT对于指导CD的临床分型、评价化疗疗效和监测病理转化均有一定的应用价值. Objective To assess the value of 18F-FDG PET/CT in clinical classification,monitoring of chemotherapeutic response and surveillance of histopathological transformation of Castleman's disease (CD).Methods Fourteen pathologically diagnosed CD patients (7 males,7 females; mean age:(45.64±14.30) years) were retrospectively reviewed.18F-FDG PET/CT was performed before chemotherapy in all patients and 4 of 14 patients were reexamined after the treatment.The study parameters included histopathological results,sites,number and highest SUVmax of the lesions.Mann-Whitney and Kruskal-Wallis tests were used for data analysis.Results Of all the 12 patients without histopathological transformation,one or more enlarged and metabolically active lymph nodes were found in each patient (SUVmax =3.94± 1.44,range:1.9-6.8),including 2 unicentric CD (UCD) and 10 multicentric CD (MCD).There was no statistically significant difference of SUVmam between UCD and MCD (4.55±3.18 vs 3.82±1.14; Z=0.22,P>0.05).There was also no significant difference of SUVmax among different pathological types (hyaline-vascular CD (4/12):3.56±0.96,plasma cell CD (6/12):4.73±1.41,mixed CD (2/12):2.30±0.57; x2 =4.74,P>0.05).For the 4 patients with follow-up PET/CT after chemotherapy,the lesion activity was normalized in 3 patients and clearly reduced in 1 patient.The SUVmax of 2 patients with histopathological transformation (10.85±2.05) was significantly higher than that without transformation (3.94± 1.44; Z=-2.19,P<0.05).Conclusion 18F-FDG PET/CT may play an important role in clinical classification,monitoring of chemotherapeutic response and surveillance of histopathological transformation of CD.
Citation statistics
Recommended Citation
GB/T 7714
付占立,张旭初,范岩,等. 18F-FDG PET/CT在Castleman病中的临床应用价值[J]. 中华核医学与分子影像杂志,2013,33(5):332-335.
APA 付占立,张旭初,范岩,张建华,&王荣福.(2013).18F-FDG PET/CT在Castleman病中的临床应用价值.中华核医学与分子影像杂志,33(5),332-335.
MLA 付占立,et al."18F-FDG PET/CT在Castleman病中的临床应用价值".中华核医学与分子影像杂志 33.5(2013):332-335.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Usage statistics
Export to Endnote
谷歌学术Similar articles in
[付占立]'s Articles
[张旭初]'s Articles
[范岩]'s Articles
百度学术Similar articles in
[付占立]'s Articles
[张旭初]'s Articles
[范岩]'s Articles
必应学术Similar articles in
[付占立]'s Articles
[张旭初]'s Articles
[范岩]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.